“Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s618. doi:10.25251/t4rkzz84.